We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China.
- Authors
Zhang, Hongyan; Wang, Linwei; Chen, Yuanyuan; Wu, Qiuji; Chen, Gaili; Shen, Xiaokun; Wang, Qun; Yan, Youqin; Yu, Yi; Zhong, Yahua; Wang, Xinghuan; Chua, Melvin L. K.; Xie, Conghua
- Abstract
<bold>Background: </bold>Patients with cancer have a higher risk of coronavirus disease 2019 (COVID-19) than noncancer patients. The authors conducted a multicenter retrospective study to investigate the clinical manifestations and outcomes of patients with cancer who are diagnosed with COVID-19.<bold>Methods: </bold>The authors reviewed the medical records of hospitalized patients who were treated at 5 hospitals in Wuhan City, China, between January 5 and March 18, 2020. Clinical parameters relating to cancer history (type and treatment) and COVID-19 were collected. The primary outcome was overall survival (OS). Secondary analyses were the association between clinical factors and severe COVID-19 and OS.<bold>Results: </bold>A total of 107 patients with cancer were diagnosed with COVID-19, with a median age of 66 years (range, 37-98 years). Lung (21 patients; 19.6%), gastrointestinal (20 patients; 18.7%), and genitourinary (20 patients; 18.7%) cancers were the most common cancer diagnoses. A total of 37 patients (34.6%) were receiving active anticancer treatment when diagnosed with COVID-19, whereas 70 patients (65.4%) were on follow-up. Overall, 52.3% of patients (56 patients) developed severe COVID-19; this rate was found to be higher among patients receiving anticancer treatment than those on follow-up (64.9% vs 45.7%), which corresponded to an inferior OS in the former subgroup of patients (hazard ratio, 3.365; 95% CI, 1.455-7.782 [P = .005]). The detrimental effect of anticancer treatment on OS was found to be independent of exposure to systemic therapy (case fatality rate of 33.3% [systemic therapy] vs 43.8% [nonsystemic therapy]).<bold>Conclusions: </bold>The results of the current study demonstrated that >50.0% of infected patients with cancer are susceptible to severe COVID-19. This risk is aggravated by simultaneous anticancer treatment and portends for a worse survival, despite treatment for COVID-19.
- Subjects
WUHAN (China); CHINA; COVID-19; SARS-CoV-2; CANCER patients; EXPOSURE therapy; MEDICAL records; THERAPEUTIC use of immunoglobulins; THERAPEUTIC use of antineoplastic agents; STEROID drugs; VIRAL pneumonia; RELATIVE medical risk; RETROSPECTIVE studies; DISEASE incidence; ANTIVIRAL agents; SEVERITY of illness index; TREATMENT effectiveness; EPIDEMICS; RESEARCH funding; TUMORS
- Publication
Cancer (0008543X), 2020, Vol 126, Issue 17, p4023
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.33042